Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung Cancer

19 Dec 2014

Abstract excerpt

The Fanconi anemia (FA) pathway is a major mechanism of homologous recombination DNA repair. The functional readout of the pathway is activation through mono-ubiquitination of FANCD2 leading to nuclear foci of repair. We have recently developed an FA triple-staining immunofluorescence based method (FATSI) to evaluate FANCD2 foci formation in formalin fixed paraffin-embedded (FFPE) tumor samples. DNA-repair...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25566506
DOI: 10.3389/fonc.2014.00368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung CancerPMID 25566506Read ↗

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.Semantic proximity Read ↗

Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination RepairSemantic proximity Read ↗

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.Semantic proximity Read ↗

Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agentsSemantic proximity Read ↗

Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.Semantic proximity Read ↗

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer TherapySemantic proximity Read ↗

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.Semantic proximity Read ↗

Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.Semantic proximity Read ↗

Generating new FANCA-deficient HNSCC cell lines by genomic editing recapitulate the cellular phenotypes of Fanconi anemiaSemantic proximity Read ↗

Generating New FANCA-Deficient HNSCC Cell Lines by Genomic Editing Recapitulate the Cellular Phenotypes of Fanconi AnemiaSemantic proximity Read ↗

Drosophila homologs of FANCD2 and FANCL function in DNA repair.Semantic proximity Read ↗

Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.